United Therapeutics director reports RSU vesting

UNITED THERAPEUTICS Corp director Christopher Patusky reported a compensation-related equity event.

Accepted by SEC EDGAR 07/13/2026 - 04:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Christopher Patusky reported a compensation-related equity event. On July 9, 2026, 650 Restricted Stock Units vested and converted on a one-for-one basis into 650 shares of common stock at a stated price of $0.00 per share. Following this vesting, he held 2,140 shares of common stock directly, in addition to 1,100 shares held indirectly by trust. The RSU award involved in this transaction was fully converted, with no remaining units from that grant.

Insider Trade Summary

650 shares exercised/converted

Exercise 2 txns

Insider PATUSKY CHRISTOPHER

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit F1, F2	650	$0.00	$0.00
Exercise	Common Stock F1	650	$0.00	$0.00
Holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 2,140 shares (Direct); Common Stock — 1,100 shares (Indirect, by Trust)

Footnotes (2)

1. F1. Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.
2. F2. Not applicable as restricted stock units do not have an expiration date.

Key Figures

RSUs vested and converted: 650 units Common shares acquired via RSU conversion: 650 shares Direct common shares after transaction: 2,140 shares +2 more

5 metrics

RSUs vested and converted 650 units Restricted Stock Units converted one-for-one into common stock on July 9, 2026

Common shares acquired via RSU conversion 650 shares Shares of common stock received upon RSU vesting on July 9, 2026

Direct common shares after transaction 2,140 shares Direct holdings of Christopher Patusky following July 9, 2026 transactions

Indirect common shares by trust 1,100 shares Indirect holdings reported as held by trust

RSU conversion price $0.0000 per share Stated transaction and conversion price for RSU-to-common conversion

Key Terms

Restricted Stock Unit, derivative security, one-for-one basis

3 terms

Restricted Stock Unit financial

"Shares received upon vesting of restricted stock units on July 9, 2026."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

one-for-one basis financial

"Restricted stock units converted on a one-for-one basis into shares of common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity transaction did UNITED THERAPEUTICS (UTHR) director Christopher Patusky report?

Christopher Patusky reported the vesting and conversion of 650 Restricted Stock Units into an equal number of common shares on July 9, 2026, a compensation-related equity event rather than an open-market trade.

How many UNITED THERAPEUTICS (UTHR) shares did Christopher Patusky acquire through this Form 4 event?

He acquired 650 shares of common stock through the vesting and one-for-one conversion of 650 Restricted Stock Units on July 9, 2026, at a stated price of $0.00 per share.

What is Christopher Patusky’s direct shareholding in UNITED THERAPEUTICS (UTHR) after the reported transactions?

After the transactions, Christopher Patusky directly held 2,140 shares of UNITED THERAPEUTICS common stock. This figure reflects his position immediately following the July 9, 2026 RSU vesting and conversion.

Does the UNITED THERAPEUTICS (UTHR) Form 4 show any open-market buys or sells by Christopher Patusky?

No. The Form 4 shows no open-market purchases or sales. It reflects a derivative exercise/conversion where Restricted Stock Units vested and converted into common stock as part of equity compensation.

What indirect holdings in UNITED THERAPEUTICS (UTHR) are reported for Christopher Patusky?

The filing reports 1,100 shares of UNITED THERAPEUTICS common stock held indirectly by Christopher Patusky through a trust, in addition to his directly held shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATUSKY CHRISTOPHER

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		650	A	$0.00(1)	2,140	D
Common Stock								1,100	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	07/09/2026		M(1)			650	07/09/2026	(2)	Common Stock	650	$0.00(1)	0.00	D

Explanation of Responses:

1. Shares received upon vesting of restricted stock units on July 9, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock.

2. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)